Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buspirone placebo Clear all
Completed Phase 2 Interventional Results available

Buspirone in Parkinson's Disease

NCT02803749
View directory record Official record
Conditions
Parkinson Disease, Anxiety
Interventions
Buspirone, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

Buspirone for Opioid Tapering

NCT03521960
View directory record Official record
Conditions
Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic, Opiate Withdrawal Syndrome
Interventions
Buspirone oral capsule, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 18, 2026, 4:51 PM EDT
Terminated Phase 3 Interventional Results available

Buspirone as a Potential Treatment for Recurrent Central Apnea

NCT00746954
View directory record Official record
Conditions
Central Apnea, Heart Failure
Interventions
Acetazolamide, Buspirone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 3 Interventional

Serotonin 1A Agonists and Cognition in Schizophrenia

NCT00178971
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
adjunctive treatment with buspirone, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)

NCT00705003
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone), Matching placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Buspirone in Reducing Shortness of Breath in Patients With Cancer

NCT00053846
View directory record Official record
Conditions
Dyspnea, Pulmonary Complications, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
buspirone hydrochloride, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 120 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Buspirone Treatment for Marijuana Dependence

NCT00875836
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Improving Ventilatory Capacity in Those With Chronic High Level SCI

NCT05041322
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence

NCT01641159
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 18, 2026, 4:51 PM EDT
Active, not recruiting Phase 2 Interventional

Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

NCT04458324
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone Hydrochloride, Buspirone placebo, Noninvasive Ventilation (NIV), Sham Non-invasive ventilation (NIV), Functional Electrical Stimulation Row Training (FESRT)
Drug · Device · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence

NCT00360191
View directory record Official record
Conditions
Marijuana Abuse
Interventions
Buspirone, Motivational enhancement therapy
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Buspirone, Stress, and Attentional Bias to Marijuana Cues

NCT02132832
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Buspirone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Buspirone for Early Satiety and Symptoms of Gastroparesis

NCT03587142
View directory record Official record
Conditions
Gastroparesis
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional

Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

NCT00174226
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Buspirone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2008 · Synced Oct 18, 2026, 4:51 PM EDT
Terminated Phase 1 Interventional

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

NCT02589340
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias, Movement Disorders
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT02101203
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, 0.5 mgTestosterone + 10 mg Buspirone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI

NCT02458469
View directory record Official record
Conditions
Spinal Cord Injury, Sleep Disordered Breathing
Interventions
Buspirone, Trazodone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 18, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional

Evaluating Buspirone to Treat Opioid Withdrawal

NCT05511909
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
Interventions
Buspirone, Lofexidine, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

NCT01821690
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 18, 2026, 4:51 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

NCT04118387
View directory record Official record
Conditions
Sleep Disordered Breathing, Able Bodied
Interventions
Acetazolamide + supplemental oxygen + PAP therapy, Zolpidem + PAP therapy, Buspirone + PAP therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 18, 2026, 4:51 PM EDT
Active, not recruiting Early Phase 1 Interventional

Transformation of Paralysis to Stepping

NCT04105114
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone, Non-invasive Spinal Cord Stimulation, Overground stepping, Gravity Neutral Device, Body Weight Supported Treadmill Training, Rolling Walker
Drug · Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 18, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

Buspirone Therapy for Localized Epilepsy

NCT01496612
View directory record Official record
Conditions
Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions
Buspirone, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Psychopharmacology for Cocaine Dependence - Buspirone

NCT01267292
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo for Buspirone, Methylphenidate, Placebo for Methylphenidate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 18, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine

NCT01639157
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
Buspirone, Placebo
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 18, 2026, 4:51 PM EDT